Department of Ophthalmology, Poznan University of Medical Sciences, Poznan, Poland.
Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.
Sci Rep. 2021 Feb 25;11(1):4522. doi: 10.1038/s41598-021-83985-5.
Retinopathy of prematurity (ROP) is potentially blinding, but screening and timely treatment can stop its progression. The data on treatment outcomes of ROP from Central and Eastern Europe are scarce. Therefore, we aimed to analyze the latest results of ROP management in Poznan medical center to update the data from this world region. In the years 2016-2019, 178 patients (350 eyes) received treatment for ROP (6.1% of the screened population). The mean gestational age was 26 weeks (range 22-31 weeks), the mean birth weight was 868 g (range 410-1890 g). The most frequent ROP stage at treatment was zone II, stage 3 + (34.9%). As the first line of treatment, 115 infants (226 eyes, 64.6%) underwent laser photocoagulation (LP); 61 infants (120 eyes, 34.3%) received intravitreal ranibizumab injections (IVR); and 2 infants (4 eyes, 0.6%) were treated simultaneously with LP and IVR. One hundred twenty-six eyes (36%) of 63 patients required retreatment: 20.4% treated with LP and 66.7% treated with IVR. Retinal detachment occurred in 14 eyes (4%). The incidence of ROP, ROP requiring treatment, and reoccurrence rates are higher in the Polish population than in Western Europe and the USA. The identified treatment patterns find increasing use of anti-VEGF agents.
早产儿视网膜病变（ROP）可能导致失明，但筛查和及时治疗可以阻止其进展。来自中东欧的 ROP 治疗结果数据稀缺。因此，我们旨在分析波兹南医疗中心最新的 ROP 管理结果，以更新该地区的数据。在 2016 年至 2019 年期间，有 178 名患者（350 只眼）接受了 ROP 治疗（占筛查人群的 6.1%）。平均胎龄为 26 周（范围 22-31 周），平均出生体重为 868 克（范围 410-1890 克）。治疗时最常见的 ROP 分期为 2 区 3 期+（34.9%）。作为一线治疗，115 名婴儿（226 只眼，64.6%）接受了激光光凝治疗（LP）；61 名婴儿（120 只眼，34.3%）接受了玻璃体内雷珠单抗注射（IVR）；2 名婴儿（4 只眼，0.6%）同时接受了 LP 和 IVR 治疗。63 名患者中有 126 只眼（36%）需要再次治疗：20.4%接受 LP 治疗，66.7%接受 IVR 治疗。14 只眼（4%）发生视网膜脱离。波兰人群的 ROP、需要治疗的 ROP 和再发率高于西欧和美国。所确定的治疗模式越来越多地使用抗血管内皮生长因子药物。
